# C-peptide

Canonical source: https://retacompare.com/encyclopedia/c-peptide

Historically considered inert; emerging evidence suggests binding to a putative GPCR with renal and microvascular protective effects.

Reference facts

Also known asConnecting PeptideCategoryHormonal & PituitaryMechanism of actionHistorically considered inert; emerging evidence suggests binding to a putative GPCR with renal and microvascular protective effects.TargetsPutative GPCRIndications under research or approvedDiagnostic marker of endogenous insulin secretion; research in diabetic neuropathyRegulatory status (reference entry)Diagnostic use; not FDA-approved as therapeuticHalf-life~30 minutesSequenceEAEDLQVGQVELGGGPGAGSLQPLALEGSLQSequence notes31-residue peptide cleaved from proinsulin during insulin maturation. Released in equimolar amounts with insulin.Molecular weight (Da)3020First reported1967
    Primary References

Wahren et al., Diabetes Care 2012 (C-peptide review)


    Explore research articles about C-peptide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Wahren et al., Diabetes Care 2012 (C-peptide review): https://pubmed.ncbi.nlm.nih.gov/22427120/